Evidence map›Paper›PMID 36841706›Full record

ReviewJournal of science and medicine in sport2023

Efforts toward the continuous monitoring of molecular markers of performance.

Charlotte Flatebo, William R Conkright, Meaghan E Beckner, Robert H Batchelor, Tod E Kippin, Jason Heikenfeld, Kevin W Plaxco

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of science and medicine in sport, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Charlotte FlateboInstitute for Collaborative Biotechnologies, University of California Santa Barbara, USA.
William R ConkrightNutrition Care Division, Madigan Army Medical Center, USA.
Meaghan E BecknerOak Ridge Institute of Science and Education, USA.
Robert H BatchelorNutromics Pty Ltd, Australia.
Tod E KippinNeuroscience Research Institute, Department of Psychological and Brain Sciences, University of California Santa Barbara, USA.
Jason HeikenfeldBiomedical, Electrical, and Chemical Engineering, Director Novel Devices Laboratory, University of Cincinnati, USA.
Kevin W PlaxcoInstitute for Collaborative Biotechnologies, University of California Santa Barbara, USA; Department of Chemistry and Biochemistry, Biological Engineering Graduate Program, University of California Santa Barbara, USA. Electronic address: kwp@ucsb.edu.
Oak Ridge Associated Universities · US

Funding

Bio-electrochemical detectors for in vivo continuous monitoringR01EB022015 · NIBIB · UNIVERSITY OF CALIFORNIA SANTA BARBARA · PI KIPPIN, TOD EDWARD, PLAXCO, KEVIN W · 2017 to 2025
$4.6M
NIBIB NIH HHS R01 EB022015
6 · The paper itself

Abstract

objectivesTechnologies supporting the continuous, real-time measurement of blood oxygen saturation and plasma glucose levels have improved our ability to monitor performance status. Our ability to monitor other molecular markers of performance, however, including the hormones known to indicate overtraining and general health, has lagged. That is, although a number of other molecular markers of performance status have been identified, we have struggled to develop viable technologies supporting their real-time monitoring in the body. Here we review biosensor approaches that may support such measurements, as well as the molecules potentially of greatest interest to monitor.

designNarrative literature review.

methodLiterature review.

resultsSignificant effort has been made to harness the specificity, affinity, and generalizability of biomolecular recognition in a platform technology supporting continuous in vivo molecular measurements. Most biosensor approaches, however, are either not generalizable to most targets, or fail when challenged in the complex environments found in vivo. Electrochemical aptamer-based sensors, in contrast, are the first technology to simultaneously achieve both of these critical attributes. In an effort to illustrate the potential of this platform technology, we both critically review the literature describing it and briefly survey some of the molecular performance markers we believe will prove advantageous to monitor using it.

conclusionsElectrochemical aptamer-based sensors may be the first truly generalizable technology for monitoring specific molecules in situ in the body and how adaptation of the platform to subcutaneous microneedles will enable the real-time monitoring of performance markers via a wearable, minimally invasive device.

Indexed as

Biosensing TechniquesWearable Electronic DevicesBiomarkersHumansMonitoring, PhysiologicBiomarkersAptamersElectrochemistryHealth monitoringPharmacokineticsTechnologyWearable electronic devices

Identifiers

PMID36841706
PMCPMC11870208
OpenAlexW4319072374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.